Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 18/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31025617 | 0.95 | GLP1R (0.64) | GLP1RHTR1ACYP2C8KCNH2PDE10A | |
| SCHEMBL24574888 | 0.95 | GLP1R (0.64) | GLP1RHTR1ACYP2C8KCNH2PDE10A | |
| SCHEMBL29748968 | 0.95 | GLP1R (0.64) | GLP1RHTR1ACYP2C8KCNH2PDE10A | |
| SCHEMBL24574887 | 0.95 | GLP1R (0.64) | GLP1RHTR1ACYP2C8KCNH2PDE10A | |
| SCHEMBL24400477 | 0.93 | GLP1R (0.68) | GLP1RHTR1ACYP2C8KCNH2PDE10A | |
| SCHEMBL31092443 | 0.93 | GLP1R (0.68) | GLP1RHTR1ACYP2C8KCNH2PDE10A | |
| SCHEMBL29749079 | 0.93 | GLP1R (0.68) | GLP1RHTR1ACYP2C8KCNH2PDE10A | |
| SCHEMBL24400468 | 0.93 | GLP1R (0.68) | GLP1RHTR1ACYP2C8KCNH2PDE10A | |
| SCHEMBL24401172 | 0.92 | GLP1R (0.63) | GLP1RHTR1ACYP2C8KCNH2PDE10A | |
| SCHEMBL25119864 | 0.91 | GLP1R (0.52) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542272-B2 | Five-membered heteroaryl-fused imidazole compound and application thereof | HANGZHOU SCIWIND BIOSCIENCES CO., LTD (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20220135588-A1 | Five-Membered Heteroaryl-Fused Imidazole Compound And Application Thereof | HANGZHOU SCIWIND BIOSCIENCES CO., LTD (CN) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135588-A1 | Five-Membered Heteroaryl-Fused Imidazole Compound And Application Thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885HTR1A 256/4885CYP2C8 1960/4885 |
| US-11542272-B2 | Five-membered heteroaryl-fused imidazole compound and application thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885HTR1A 256/4885CYP2C8 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.